2024-02-05 04:01:47 ET
Summary
- Bristol-Myers Squibb is pursuing aggressive M&A to address its growth challenges and loss of exclusivity for its top-selling drug Revlimid, ahead of more expirations due.
- The company's net debt load is substantial, and it relies heavily on a few key drugs for the majority of its sales, creating a risk as pipeline conversion is key.
- Recent acquisitions and deals have added to the company's debt and raised concerns about its near-term medium-term earnings picture.
Days before Christmas, I believed that Bristol-Myers Squibb ( BMY ) was pursuing aggressive M&A as a riskier strategy in order to fix its growth challenges. Battling loss of exclusivity from its once top-selling drug Revlimid, and with more expirations due, the company has focused on inorganic efforts to stem sales declines....
Read the full article on Seeking Alpha
For further details see:
Bristol-Myers Squibb: All Focus On Execution